Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 10.72
(1.61%)
CNY 10.72
(1.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.42 Billion CNY | -3.14% |
| 2022 | 4.56 Billion CNY | 2.55% |
| 2021 | 4.45 Billion CNY | -5.84% |
| 2020 | 4.73 Billion CNY | 25.55% |
| 2019 | 3.76 Billion CNY | 17.81% |
| 2018 | 3.19 Billion CNY | 44.94% |
| 2017 | 2.2 Billion CNY | 4.48% |
| 2016 | 2.11 Billion CNY | 7.33% |
| 2015 | 1.96 Billion CNY | 37.49% |
| 2014 | 1.43 Billion CNY | -4.83% |
| 2013 | 1.5 Billion CNY | 86.07% |
| 2012 | 808.3 Million CNY | 56.43% |
| 2011 | 516.7 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 4.45 Billion CNY | 0.26% |
| 2024 Q1 | 4.54 Billion CNY | 2.74% |
| 2024 Q2 | 4.44 Billion CNY | -2.31% |
| 2023 Q3 | 4.12 Billion CNY | -13.18% |
| 2023 Q4 | 4.42 Billion CNY | 7.18% |
| 2023 FY | 4.42 Billion CNY | -3.14% |
| 2023 Q1 | 4.71 Billion CNY | 3.18% |
| 2023 Q2 | 4.75 Billion CNY | 0.87% |
| 2022 Q1 | 4.57 Billion CNY | 2.75% |
| 2022 FY | 4.56 Billion CNY | 2.55% |
| 2022 Q4 | 4.56 Billion CNY | 3.71% |
| 2022 Q3 | 4.4 Billion CNY | -5.1% |
| 2022 Q2 | 4.64 Billion CNY | 1.41% |
| 2021 FY | 4.45 Billion CNY | -5.84% |
| 2021 Q2 | 4.27 Billion CNY | -5.52% |
| 2021 Q1 | 4.52 Billion CNY | -4.28% |
| 2021 Q4 | 4.45 Billion CNY | -0.71% |
| 2021 Q3 | 4.48 Billion CNY | 4.87% |
| 2020 Q3 | 4.16 Billion CNY | 0.9% |
| 2020 Q2 | 4.12 Billion CNY | -9.76% |
| 2020 Q1 | 4.57 Billion CNY | 21.28% |
| 2020 FY | 4.73 Billion CNY | 25.55% |
| 2020 Q4 | 4.73 Billion CNY | 13.7% |
| 2019 Q3 | 3.31 Billion CNY | 5.07% |
| 2019 Q4 | 3.76 Billion CNY | 13.69% |
| 2019 FY | 3.76 Billion CNY | 17.81% |
| 2019 Q2 | 3.15 Billion CNY | -0.54% |
| 2019 Q1 | 3.17 Billion CNY | -0.84% |
| 2018 Q2 | 2.36 Billion CNY | 8.63% |
| 2018 Q3 | 2.54 Billion CNY | 8.0% |
| 2018 FY | 3.19 Billion CNY | 44.94% |
| 2018 Q4 | 3.19 Billion CNY | 25.45% |
| 2018 Q1 | 2.17 Billion CNY | -1.52% |
| 2017 Q2 | 1.59 Billion CNY | -14.72% |
| 2017 FY | 2.2 Billion CNY | 4.48% |
| 2017 Q4 | 2.2 Billion CNY | 19.15% |
| 2017 Q3 | 1.85 Billion CNY | 15.97% |
| 2017 Q1 | 1.87 Billion CNY | -11.34% |
| 2016 Q1 | 1.87 Billion CNY | -4.89% |
| 2016 FY | 2.11 Billion CNY | 7.33% |
| 2016 Q4 | 2.11 Billion CNY | 0.16% |
| 2016 Q3 | 2.1 Billion CNY | 7.27% |
| 2016 Q2 | 1.96 Billion CNY | 5.03% |
| 2015 Q1 | 1.47 Billion CNY | 3.28% |
| 2015 FY | 1.96 Billion CNY | 37.49% |
| 2015 Q4 | 1.96 Billion CNY | 27.09% |
| 2015 Q2 | 1.61 Billion CNY | 9.2% |
| 2015 Q3 | 1.54 Billion CNY | -4.08% |
| 2014 Q2 | 1.16 Billion CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 1.43 Billion CNY | 0.0% |
| 2014 FY | 1.43 Billion CNY | -4.83% |
| 2013 FY | 1.5 Billion CNY | 86.07% |
| 2012 FY | 808.3 Million CNY | 56.43% |
| 2011 FY | 516.7 Million CNY | 0.0% |